| Bioactivity | iRGD peptide 1 TFA is the prototypic tumor-specific tissue-penetrating peptide, which delivers drugs deep into extravascular tumor tissue. iRGD peptide 1 TFA has anti-metastatic activity[1]. | ||||||
| Invitro | iRGD peptide 1 (iRGD) inhibits migration of tumor cells and caused chemorepulsion in vitro in a CendR- and NRP-1-dependent manner. iRGD peptide 1 induces dramatic collapse of cellular processes and partial cell detachment, resulting in the repellent activity. These effects are prominently displayed when the cells are seeded on fibronectin, suggesting a role of CendR in functional regulation of integrins[1]. | ||||||
| Name | iRGD peptide 1 TFA | ||||||
| Sequence | Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys | ||||||
| Shortening | CRGDKGPDC | ||||||
| Formula | C37H60F3N13O16S2 | ||||||
| Molar Mass | 1064.08 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
iRGD peptide 1 TFA
CAS: F: C37H60F3N13O16S2 W: 1064.08
iRGD peptide 1 TFA is the prototypic tumor-specific tissue-penetrating peptide, which delivers drugs deep into extravasc
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.